Tianshili was founded in 1994. It is a high-tech enterprise group guided by internationalization, with the big health industry as the main line, the life medicine industry as the core, and the life health industry as the coordinated. The core enterprise, Tianshili Pharmaceutical Group Co., Ltd., was listed on the Shanghai Stock Exchange in 2002.

Tianshili Pharmaceutical Group focuses on developing the life medicine industry in the big health industry system. Based on the technical positioning of large biomedicine, regenerative medicine and biomedical engineering, we adhere to the development of high-tech, high intelligence and high-end. Standardization and intelligence are achieved through a series of modern Chinese medicine internationalization guide industries represented by compound Danshen Drip Pills. The company has created a high-speed drop pill production line and a digital intelligent extraction production line of traditional Chinese medicine. On the basis of innovative modern Chinese medicine, it has linked international cutting-edge technologies through the "four-in-one" R&D model of independent research and development, cooperative research and development, product introduction, and investment market licensing priority. Do special and optimize the study of medicines, and make new and high-quality biological medicines. Positioning with optional urgent needs, fair self-payment, and technological upgrades, we will foresee the layout of new businesses such as cell therapy, Internet chronic diseases + digital therapy, and high-intensity focus ultrasound technology, and create integrated around the prevention, diagnosis, treatment and health of major chronic diseases. Solution, establish a health management function network.

Tianshili Big Health Industry Investment Group focuses on developing the life and health industry in the big health industry system. Closely focusing on the core elements of healthy life and personalized users' needs, taking resource industries as a breakthrough, and taking Guotai Wine Industry Group as the leader, it will drive the development of Diboer tea treasure series and healthy functional foods and C-cell vibrant mineral water industry, through Technological innovation and product culture are demonstrated to enhance the consumption experience of healthy products.

Tianshili adheres to industry-oriented, finance-oriented, and industrial-financial interaction. Establish an industrial capital platform - Tianshili Capital, positioned with "industry + capital", and focuses on "specialization, specialization and innovation" to strengthen, supplement and create chains, empower real industries to innovate and upgrade, and realize value creation and operation. Focusing on the fields of cardiovascular, tumors, digestive and metabolism, through investment linkage of 4D (Diagnosis diagnostic screening, Drug innovative drugs, Device medical devices and wearable devices, Digital digital therapy), we will build a great health value that is linked and empowered by each other. Ecology.

Looking to the future, Tianshili will use modern science and technology and platforms such as artificial intelligence and big data to accelerate the "two transformations and one improvement" and transform into innovative and creative enterprises and smart service enterprises, from "product manufacturing as the core" to " With intelligent manufacturing with clustered products and systematic industrial chain as the core, we will upgrade, focus on building a "big health" ecosystem, we will be committed to innovating and developing, and contribute to the construction of a "healthy China".